Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mr Tsuchiya of Eisai Disapproves Virtual Permission of Off-label Use of Generics Not Approved for the Same Indications as Their Original Drugs
February 6, 2012
- Chugai Pharmaceutical Dec 2011 Sales Decline After Earthquake Despite Steady Sales Abroad
February 6, 2012
- Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
- Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
- Eisai's Apr-Dec Sales Down 17% on 50% Drop in Aricept Sales
February 3, 2012
- Pfizer to Offer Financial, Technical Support for Early Stage Development to External Institution
February 3, 2012
- Apr-Dec Sales Up 4%, Profits Show 2-Digit Increase due to Growth in Vesicare: Astellas
February 3, 2012
- Chugai to Restructure Marketing Div. to Achieve Targets in “Sunrise 2012” Plan
February 3, 2012
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
- Daiichi Sankyo Says “No Major Impact” from Ranbaxy’s Relinquishment of Marketing Exclusivity
February 1, 2012
- Shuichi Watanabe to Become President, Sadatake Kumakura Chairman: Medipal HD
February 1, 2012
- Apr-Dec Net Profits Down 78% due to Ranbaxy Settlement Fee: Daiichi Sankyo
February 1, 2012
- Kyowa Hakko Kirin Withdraws Application for Additional Indication for Nesp
February 1, 2012
- Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…